Protein tyrosine phosphatase 1B inhibitors for diabetes

Nature Reviews Drug Discovery

Volumn 1, Issue 9, 2002, Pages 696-709

  Johnson, Theodore O ^a   Ermolieff, Jacques ^a   Jirousek, Michael R ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 CARBOMETHOXYBENZOIC ACID DERIVATIVE; 2 OXALYLAMINOBENZOIC ACID DERIVATIVE; ANTISENSE OLIGONUCLEOTIDE; BENZOIC ACID DERIVATIVE; DIFLUOROMETHYLENE PHOSPHONIC ACID DERIVATIVE; INSULIN; LEPTIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PHOSPHONIC ACID DERIVATIVE; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE INHIBITOR; UNCLASSIFIED DRUG; ENZYME INHIBITOR; PROTEIN TYROSINE PHOSPHATASE 1B;

DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; GENE LINKAGE DISEQUILIBRIUM; HUMAN; INCIDENCE; INHIBITION KINETICS; INSULIN RESISTANCE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TARGETING; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; CHEMISTRY; DRUG ANTAGONISM; GENETICS; METABOLISM; MOLECULAR BIOLOGY; PHYSIOLOGY; STRUCTURE ACTIVITY RELATION;

DIABETES MELLITUS, TYPE 2; ENZYME INHIBITORS; HUMANS; MOLECULAR BIOLOGY; OBESITY; PROTEIN-TYROSINE-PHOSPHATASE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0036715628     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd895     Document Type: Review

References (95)

1. Zimmet, P., Alberti, K. G. M. M. & Shaw, J. Global and societal implications of the diabetes epidemic. Nature 414, 782-787 (2001).
2. Sinha, R. et al. Prevalence of impaired glucose tolerance among children and adolescents with marked obesity. N. Engl. J. Med. 346, 802-810 (2002).
3. Rocchini, A. P. Childhood obesity and a diabetes epidemic. N. Engl. J. Med. 346, 854-855 (2002).
4. Dunstan, D. W. et al. The rising prevalence of diabetes and impaired glucose tolerance. The Australian diabetes, obesity and lifestyle study. Diabetes Care 25, 829-834 (2002).
5. Groop, L. & Orho-Melander, M. The dysmetabolic syndrome. J. Int. Med. 250, 105-120 (2001).
6. Poitout, V. & Robertson, P. R. Minireview: secondary β-cell failure in type 2 diabetes - a convergence of glucotoxity and lipotoxicity. Endocrinology 143, 339-342 (2002).
7. Weyer, C., Tartanni, P. A., Bogardus, C. & Pratley, R. E. Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development. Diabetes Care 24, 89-94 (2001).
8. Stumvoll, M., Fritsche, A. & Haring, H. U. Clinical characterization of insulin secretion as the basis for genetic analyses. Diabetes 51 (Suppl. 1), S122-S129 (2002).
9. Uusitupa, M. et al. The Finnish Diabetes Prevention Study. Br. J. Nutr. 83 (Suppl. 1), S137-S142 (2000).
10. The Diabetes Prevention Study Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346, 393-403 (2002).
11. Heine, R. J. & Dekker, J. M. Beyond postprandial hyperglycaemia: metabolic factors associated with cardiovascular disease. Diabetologia 45, 461-475 (2002).
12. Marx, J. Unraveling the causes of diabetes. Science 296, 686-689 (2002).
13. Saltiel, A. R. & Kahn, C. R. Insulin signaling and the regulation of glucose and lipid metabolism. Nature 414, 799-806 (2001).
14. Obici, S., Feng, Z., Karkanias, G., Baskin, D. G. & Rossetti, L. Decreasing hypothalamic insulin receptors causes hyperphagia and insulin resistance in rats. Nature Neurosci. 5, 566-572 (2002).
15. Saltiel, A. R. & Pessin, J. E. Insulin signaling pathways in time and space. Trends Cell Biol. 12, 65-71 (2002).
16. Bryant, N. J., Govers, R. & James, D. E. Regulated transport of the glucose transporter GLUT4. Nature Rev. Mol. Cell Biol. 3, 267-277 (2002).
17. Smith, U. Impaired ('diabetic') insulin signaling and action occur in fat cells long before glucose intolerance - is insulin resistance initiated in the adipose tissue? Int. J. Obes. Relat. Metab. Disord. 26, 897-904 (2002).
18. Ostman, A. & Bohmer, F. D. Regulation of receptor tyrosine kinase signaling by protein tyrosine phosphatases. Trends Cell Biol. 11, 258-266 (2001).
19. Cheng, A., Dube, N., Gu, F. & Tremblay, M. L. Coordinated action of protein tyrosine phosphatases in insulin signal transduction. Eur. J. Biochem. 269, 1050-1059 (2002).
20. Goldstein, B. J., Bittner-Kowalczyk, A., White, M. F. & Harbeck, M. Tyrosine dephosphorylation and deactivation of insulin receptor substrate-1 by protein-tyrosine phosphatase 1B. Possible facilitation by the formation of a ternary complex with the GRB2 adaptor protein. J. Biol. Chem. 275, 4283-4289 (2000).
21. Wu, X. et al. Depot-specific variation in protein-tyrosine phosphatase activities in human omental and subcutaneous adipose tissue: a potential contribution to differential insulin sensitivity. J. Clin. Endocrinol. Metab. 86, 5973-5980 (2001).
22. Cheung, A. et al. Marked impairment of protein tyrosine phosphatase 1B activity in adipose tissue of obese subjects with and without type 2 diabetes mellitus. J. Lab. Clin. Med. 134, 115-123 (1999).
23. Forsell, P. K. A. L., Boie, Y., Montalibet, J., Collins, S. & Kennedy, B. P. Genomic characterization of the human and mouse protein tyrosine phosphatase-1B genes. Gene 260, 145-153 (2000).
24. Mok, A. et al. A single nucleotide polymorphism in protein tyrosine phosphatase PTP1B is associated with protection from diabetes or impaired glucose tolerance in Oji-Cree. J. Clin. Endocrinol. Metab. 87, 724-727 (2002).
25. Di Paola, R. et al. A variation in 3′UTR of hPTP1B increases specific gene expression and associates with insulin resistance. Am. J. Hum. Genet. 70, 806-812 (2002).
26. Echwald, S. M. et al. A P387L variant in protein tyrosine phosphatase-1B (PTP1B) is associated with type 2 diabetes and impaired serine phosphorylation of PTP1B in vitro. Diabetes 51, 1-6 (2002).
27. Goldstein, B. J. Protein tyrosine phosphatase 1B (PTP1B): a novel therapeutic target for type 2 diabetes mellitus, obesity and related states of insulin resistance. Curr. Drug Targets Immune Endocr. Metab. Disord. 1, 265-275 (2001).
28. Ukkola, O. & Santaniemi, M. Protein tyrosine phosphatase 1B: a new target for the treatment of obesity and associated co-morbidities. J. Int. Med. 251, 467-475 (2002).
29. Egawa, K. et al. Protein-tyrosine phosphatase-1B negatively regulates insulin signaling in 16 myocytes and Fao hepatoma cells. J. Biol. Chem. 276, 10207-10211 (2001).
30. Chen, H. et al. Protein-tyrosine phosphatases PTP1B and SYP are modulators of insulin-stimulated translocation of GLUT4 in transfected rat adipose cells. J. Biol. Chem. 272, 8026-8031 (1997).
31. Venable, C. L. et al. Overexpression of protein-tyrosine phosphatase-1B in adipocytes inhibits insulin-stimulated phosphoinositide 3-kinase activity without altering glucose transport or Akt/Protein kinase B activation. J. Biol. Chem. 275, 18318-18326 (2000).
32. Mahadev, K. et al. Hydrogen peroxide generated during cellular insulin stimulation is integral to activation of the distal insulin signaling cascade in 3T3-L1 adipocytes. J. Biol. Chem. 276, 48662-48669 (2001).
33. Tao, J., Malbon, C. C. & Wang, H. Insulin stimulates tyrosine phosphorylation and inactivation of protein tyrosine phosphatase 1B in vivo. J. Biol. Chem. 276, 29520-29525 (2001).
34. Salmeen, A., Andersen, J. N., Myers, M. P., Tonks, N. K. & Barford, D. Molecular basis for the dephosphorylation of the activation segment of the insulin receptor by protein tyrosine phosphatase 1B. Mol. Cell 7, 615-621 (2001).
35. Barford, D. The mechanism of protein kinase regulation by protein phosphatases. Biochem. Soc. Trans. 29, 385-391 (2001)
36. Xie, L., Zhang, Y. L. & Zhang, Z. Y. Design and characterization of an improved protein tyrosine phosphatase substrate-trapping mutant. Biochemistry 41, 4032-4039 (2002).
37. Myers, M. P. et al. TYK2 and JAK2 are substrates of protein-tyrosine phosphatase 1B. J. Biol. Chem. 276, 47771-47774 (2001).
38. Haj, F. G., Verveer, P. J., Squire, A., Neel, B. G. & Bastiaens, P. I. Imaging sites of receptor dephosphorylation by PTP1B on the surface of the endoplasmic reticulum. Science 295, 1708-1711 (2002).
39. Gill, G. N. A pit stop at the ER. Science 295, 1654-1655 (2002).
40. Dadke, S. & Chernoff, J. Interaction of protein tyrosine phosphatase (PTP) 1B with its substrates is influenced by two distinct binding domains. Biochem. J. 364, 377-383 (2002).
41. Elchebly M. et al. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science 283, 1544-1548 (1999).
42. Klaman, L. D. et al. Increased energy expenditure, decreased adiposity, and tissue-specific insulin sensitivity in protein-tyrosine phosphatase 1B-deficient mice. Mol. Cell. Biol. 20, 5479-5489 (2000).
43. Kaszubska, W. et al. The role of PTP1B in leptin signalling. Keystone Symposia: Diabetes Mellitus: Molecular Mechanisms, Genetics and New Therapies Jan 10-16 226, 81 (2002).
44. Zabolotny, J. M. et al. PTP1B regulates leptin signal transduction in vivo. Dev. Cell 2, 489-495 (2002).
45. Cook, W. S. & Unger, R. H. Protein tyrosine phosphatase 1B: a potential leptin resistance factor of obesity. Dev. Cell 2, 385-387 (2002).
46. Cheng, A. et al. Attenuation of leptin action and regulation of obesity by protein tyrosine phosphatase 1B. Dev. Cell 2, 497-503 (2002).
47. Zinker, B. A. et al. Reduction of protein tyrosine phosphatase 1B normalizes glucose and improves insulin sensitivity in diabetic mice. Proc. Natl Acad. Sci. USA 99, 11357-11362 (2002).
48. Tonks, N. K., Diltz, C. D. & Fischer, E. H. Purification of the major protein-tyrosine phosphatases of human placenta. J. Biol. Chem. 263, 6722-6730 (1988).
49. Barford, D., Flint, A. J. & Tonks, N. K. Crystal structure of human protein tyrosine phosphatase 1B. Science 263, 1397-1404 (1994).
50. Jia, Z., Barford, D., Flint, A. J. & Tonks, N. K. Structural basis for phosphotyrosine peptide recognition by protein tyrosine phosphatase 1B. Science 268, 1754-1758 (1998).
51. Groves, M. R., Yao, Z. J., Roller, P. P., Burke, T. R. Jr & Barford, D. Structural basis for inhibition of the protein tyrosine phosphatase 1B by phosphotyrosine peptide mimetics. Biochemistry 37, 17773-17783 (1998).
52. Pannifer, A. D. B., Flint, A. J., Tonks, N. K. & Barford, D. Visualization of the cysteinyl-phosphate intermediate of a protein-tyrosine phosphatase by X-ray crystallography. J. Biol. Chem. 273, 10454-10462 (1998).
53. Puius, Y. A. et al. Identification of a second aryl phosphate binding site in protein-tyrosine phosphatase 1B: a paradigm for inhibitor design. Proc. Natl Acad. Sci. USA 94, 13420-13425 (1997).
54. Hadjuk, P. J., Meadows, R. P. & Fesik, S. W. Discovering high affinity ligands for proteins. Science 278, 497-499 (1997).
55. Iversen, L. F. et al. Structure based design of a low molecular weight, non-phosphorous, non-peptide, and highly selective inhibitor of protein-tyrosine phosphatase 1B. J. Biol. Chem. 275, 10300-10307 (2000).
56. Asante-Appiah, E. et al. The YRD motif is a major determinant of substrate and inhibitor specificity in T-cell protein-tyrosine phosphatase. J. Biol. Chem. 276, 26036-26043 (2001).
57. Peters, G. H. et al. Residue 259 is a key determinant of substrate specificity of protein-tyrosine phosphatases 1B and α. J. Biol. Chem. 275, 18201-18209 (2000).
58. Iversen, L. F. et al. Steric hindrance as a basis for structure-based design of selective inhibitors of protein tyrosine phosphatases. Biochemistry 40, 14812-14820 (2001).
59. Iversen, L. F. et al. Structure determination of T cell protein-tyrosine phosphatase. J. Biol. Chem. 277, 19982-19990 (2002).
60. Ibarra-Sanchez, M. D. et al. Murine embryonic fibroblasts lacking TC-PTP display delayed G1 phase through defective NF-κB activation. Oncogene 20, 4728-4739 (2001).
61. You-Ten, K. E. et al. Impaired bone marrow microenvironment and immune function in T cell protein tyrosine phosphatase-deficient mice. J. Exp. Med. 18, 683-693 (1997).
62. Blaskovitch, M. A. & Kim, H.-O. Recent advances in discovery and development of protein tyrosine phosphatase inhibitors. Expert Opin. Ther. Patents 12, 871-905 (2002).
63. Burke, T. R., Kole, H. K. & Roller, P. P. Potent inhibition of insulin receptor dephosphorylation by a hexamer peptide containing the phosphotyrosyl mimetic F2Pmp. Biochem. Biophys. Res. Commun. 204, 129-134 (1994).
64. Burke, T. R. Jr et al. Small molecule interactions with protein-tyrosine phosphatase PTP1B and their use in inhibitor design. Biochemistry 35, 15989-15996 (1996).
65. Taing, M. et al. Potent and highly selective inhibitors of the protein tyrosine phosphatase 1B. Biochemistry 38, 3793-3803 (1999).
66. Jia, Z. et al. Structure of protein tyrosine phosphatase 1B in complex with inhibitors bearing two phosphotyrosine mimetics. J. Med. Chem. 44, 4584-4594 (2001).
67. Bayly, C. & Ohkubo, M. Sulfur substituted aryldifluoromethylphosphonic acids as PTP1B inhibitors. Patent WO 01/70754 (2001).
68. Leblanc, Y., Dufresne, C., Gauthier, J. Y. & Young, R. Aromatic phosphonates as protein tyrosine phosphatase 1B (PTP1B) inhibitors. Patent WO 01/46204 (2001).
69. Shen, K. et al. Acquisition of a specific and potent PTP1B inhibitor from a novel combinatorial library and screening procedure. J. Biol. Chem. 276, 47311-47319 (2001).
70. Leblanc, Y., Dufresne, C., Roy, P. & Wang, Z. Phosphonic and carboxylic acid derivatives as inhibitors of protein tyrosine phosphatase-1B. Patent WO 00/69889 (2000).
71. Burke T. R. Jr et al. Enantioselective synthesis of nonphosphorous-containing phosphotyrosyl mimetics and their use in the preparation of tyrosine phophatase inhibitory peptides. Tetrahedron 54, 9981-9994 (1998).
72. Bleasdale, J. E. et al. Small molecule peptidomimetics containing a novel phosphotyrosine bioisostere inhibit protein tyrosine phosphatase 1B and augment insulin action. Biochemistry 40, 5642-5654 (2001).
73. Larsen, S. D. et al. Synthesis and biological activity of a novel class of small molecular weight peptidomimetic competitive inhibitors of protein tyrosine phosphatase 1B. J. Med. Chem. 45, 598-622 (2002).
74. Liljebris, C., Larsen, S. D., Ogg, D., Palazuk, B. J. & Bleasedale, J. E. Investigation of potential bioisosteric replacements for the carboxyl groups of peptidomimetic inhibitors of protein tyrosine phosphatase 1B: identification of a tetrazole-containing inhibitor with cellular activity. J. Med. Chem. 45, 1785-1796 (2002).
75. Andersen, et al. 2-(Oxalylamino)benzoic acid is a general, competitive inhibitor of protein tyrosine phosphatases. J. Biol. Chem. 275, 7101-7108 (2000).
76. Iversen, L. F. et al. Structure based design of a low molecular weight, non-phosphorous, non-peptide, and highly selective inhibitor of protein-tyrosine phosphatase 1B. J. Biol. Chem. 275, 10300-10307 (2000).
77. Andersen, H. S. Method of inhibiting protein tyrosine phosphatase 1B and/or T-cell protein tyrosine phosphatase and/or other PTPases with Asp residue at position 48. Patent WO 01/17516 (2001).
78. Lui, G. et al. Discovery of competitive, potent, and selective protein tyrosine phosphatase 1B inhibitors. 223rd American Chemical Society National Meeting, Orlando, Florida, April 7-11, 2002 MEDI-002 (2002).
79. Wrobel, J. et al. PTP1B inhibition and antihyperglycemic activity in the ob/ob mouse model of novel 11-arylbenzo[b]naphtha[2,3-d]furans and 11-arylbenzo[b]naphto[2,3-d]thiophenes. J. Med. Chem. 42, 3199-3202 (1999).
80. Reuters Business Report. (10 Jun 2002).
81. McGovern, S. L., Caselli, E., Grigorieff, N. & Shoichet, B. K. A common mechanism underlying promiscuous inhibitors from virtual and high throughput screening. J. Med. Chem. 45, 1712-1722 (2002).
82. Doman, T. N. et al. Molecular docking and high throughput screening for novel inhibitors of protein tyrosine phosphatase-1B. J. Med. Chem. 45, 2213-2221 (2002).
83. Lubben, T., Clampit, J., Stashko, M., Trevillyan, J. & Jirousek, M. R. in Current Protocols in Pharmacology Vol. 8 Ch. 3 (Emma, S. I. et al.) 1-18 (John Wiley, New York, 2001).
84. Cornish-Bowden, A. Fundamentals of Enzyme Kinetics (Portland Press, London, 1995).
85. Copeland, R. A. Enzymes: a Practical Introduction to Structure, Mechanism, and Data Analysis 2nd edn (Wiley-VCH, New York, 2000).
86. Bieth, J. G. Theoretical and practical aspects of proteinase inhibition kinetics. Methods Enzymol. 248, 59-84 (1995).
87. Zhang, Y. L., Keng, Y. F., Zhao, Y., Wu, L. & Zhang, Z. Y. Suramin is an active site-directed, reversible, and tight-binding inhibitor of protein-tyrosine phosphatases. J. Biol. Chem. 273, 12281-12287 (1998).
88. Lu, B. et al. Enhanced sensitivity of insulin-resistant adipocytes to vanadate is associated oxidative stress and decreased reduction of vanadate (+5) to vanadyl (+4). J. Biol. Chem. 276, 35589-35598 (2001).
89. Huyer, G. et al. Mechanism of inhibition of protein-tyrosine phosphatases by vanadate and pervanadate. J. Biol. Chem. 272, 843-851 (1997).
90. Crans, D., Bunch, R. L. & Theisen, L. A. Interaction of trace levels of vanadium (IV) and vanadium (V) in biological systems. J. Am. Chem. Soc. 111, 7597-7607 (1989).
91. Lipinski, C. A., Lombardo, F., Dominy, B. W. & Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 23, 3-25 (1997).
92. Palm, K., Stenberg, P., Luthman, K. & Artursson, P. Polar molecular surface properties predict the intestinal absorption of drugs in humans. Pharm. Res. 14, 568-571 (1997).
93. Veber, D. F. et al. Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem. 45, 2615-2623 (2002).
94. Pei, Z. et al. (2R)-2-(2′,6′-dichloro-4′-dibenzo(b,d furan-4″-ylphenoxy) -3-phenylpropanoic acid (A-321842) as a protein tyrosine phosphatase 1B (PTP1B) inhibitor with anti-diabetic effects in ob/ob mice. Diabetes 50 (Suppl. 1), 1524-P (2001).
95. Burkey, B. F. et al. Pharmacogenomic evaluation of a putative orally active PTP1B inhibitor using ob/ob mice reveals an alternative mechanism of action. Diabetes 51 (Suppl. 2), 138-OR (2002).